The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
STAT3 SIGNALING: Anticancer Strategies and Challenges
Open accessAbstract
Multiple lines of evidence place STAT3 at a central node in the development, progression, and maintenance of many human tumors, and STAT3 has been validated as an anti-cancer target in several contexts. STAT3 modulates the transcription of a variety of genes involved in the regulation of critical functions, including cell differentiation, proliferation, apoptosis, angiogenesis, metastasis, and immune responses. For many cancers, elevated levels of activated STAT3 have been associated with a poor prognosis. We review approaches that have been pursued to target STAT3, and we highlight some of the promises and challenges associated with developing an anticancer drug that might therapeutically inhibit the STAT3 signaling pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 11×
“STAT3 is structurally typical of the STAT family: an N-terminal coiled-coiled domain involved in protein–protein interactions; a DNA binding domain; a Src homology-2 (SH-2) domain; and a C-terminal transactivation domain (5, 22).”
BackgroundInfluentialBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
The JAK-STAT Signaling Pathway: Input and Output Integration
Murray, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2623 · Cited by 1,179
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Aggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 649
SOCS regulation of the JAK/STAT signalling pathway
Croker, B. A., Kiu, H., & Nicholson, S. E. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.010 · Cited by 611
Inhibitors of Cytokine Signal Transduction
Wormald, S., & Hilton, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r300030200 · Cited by 440
Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis
Silva, C. M. (2004) · Oncogene · doi:10.1038/sj.onc.1208159 · Cited by 403
STAT3 as a central mediator of neoplastic cellular transformation
Frank, D. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.017 · Cited by 364
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348
STAT‐mediated EGFR signaling in cancer
Quesnelle, K. M., Boehm, A. L., & Grandis, J. R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21475 · Cited by 295
Self-citationTargeting Stat3 in cancer therapy
Jing, N., & Tweardy, D. J. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200507000-00002 · Cited by 278
Alvarez, J. V., Greulich, H., Sellers, W. R., Meyerson, M., & Frank, D. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3757 · Cited by 240
Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
Regis, G., Pensa, S., Boselli, D., Novelli, F., & Poli, V. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.06.004 · Cited by 236
Santos, F. P. S., Kantarjian, H. M., Jain, N., Manshouri, T., Thomas, D. A., Garcia-Manero, G., Kennedy, D., Estrov, Z., Cortes, J., & Verstovsek, S. (2010) · Blood · doi:10.1182/blood-2009-10-246363 · Cited by 233
STAT3 as a therapeutic target in head and neck cancer
Leeman, R. J., Lui, V. W. Y., & Grandis, J. R. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.231 · Cited by 223
Self-citationRegulation of cytokine signaling pathways by PIAS proteins
Shuai, K. (2006) · Cell Research · doi:10.1038/sj.cr.7310027 · Cited by 221
Germain, D., & Frank, D. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2491 · Cited by 220
Ram, P. T., & Iyengar, R. (2001) · Oncogene · doi:10.1038/sj.onc.1204186 · Cited by 133
Sen, B., Saigal, B., Parikh, N. U., Gallick, G. E., & Johnson, F. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2944 · Cited by 132
Chen, L. F., Cohen, E. E. W., & Grandis, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2318 · Cited by 120
Self-citationTherapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Zhang, X., Zhang, J., Wang, L., Wei, H., & Tian, Z. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-149 · Cited by 115
Zhang, C., Li, B., Zhang, X., Hazarika, P., Aggarwal, B. B., & Duvic, M. A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.86 · Cited by 112
Leeman‐Neill, R. J., Wheeler, S., Singh, S. V., Thomas, S. M., Seethala, R. R., Neill, D. B., Panahandeh, M. C., Hahm, E., Joyce, S. C., Sen, M., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp211 · Cited by 108
Self-citationLeeman‐Neill, R. J., Cai, Q., Joyce, S. C., Thomas, S. M., Bhola, N. E., Neill, D. B., Arbiser, J. L., & Grandis, J. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0333 · Cited by 106
Self-citationThe JAK kinases: Not just another kinase drug discovery target
Wilks, A. F. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.07.020 · Cited by 97
Nucleocytoplasmic shuttling of persistently activated STAT3
Herrmann, A., Vogt, M., Mönnigmann, M., Clahsen, T., Sommer, U., Haan, S., Poli, V., Heinrich, P. C., & Müller-Newen, G. (2007) · Journal of Cell Science · doi:10.1242/jcs.03482 · Cited by 94
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein
Fletcher, S., Drewry, J. A., Shahani, V. M., Page, B. D. G., & Gunning, P. T. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-044 · Cited by 90
Koppikar, P., Lui, V. W. Y., Man, D., Xi, S., Chai, R. L., Nelson, E. G., Tobey, A. B. J., & Grandis, J. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1328 · Cited by 82
Self-citationBoehm, A. L., Sen, M., Seethala, R. S., Gooding, W. E., Freilino, M. L., Wong, S. M. Y., Wang, S., Johnson, D. E., & Grandis, J. R. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044636 · Cited by 74
Self-citationLui, V. W. Y., Boehm, A. L., Koppikar, P., Leeman‐Neill, R. J., Johnson, D. E., Ogagan, M. J., Childs, E. E., Freilino, M. L., & Grandis, J. R. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032284 · Cited by 66
Self-citationEgloff, A. M., & Grandis, J. R. (2009) · Journal of Oncology · doi:10.1155/2009/896407 · Cited by 64
Self-citationLack of toxicity of a STAT3 decoy oligonucleotide
Sen, M., Tosca, P. J., Zwayer, C., Ryan, M. J., Johnson, J. D., Knostman, K. A. B., Giclas, P. C., Peggins, J. O., Tomaszewski, J. E., McMurray, T. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0823-6 · Cited by 53
Self-citationWoolson, H. D., Thomson, V. S., Rutherford, C. L., Yarwood, S. J., & Palmer, T. M. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.07.009 · Cited by 52
Seethala, R. R., Gooding, W. E., Handler, P. N., Collins, B. M., Zhang, Q. H., Siegfried, J. M., & Grandis, J. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1543 · Cited by 50
Self-citationNaviglio, S., Gesto, D. D., Illiano, F., Chiosi, E., Giordano, A., Illiano, G., & Spina, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22288 · Cited by 40
Cross-talk between α1B-Adrenergic Receptor (α1BAR) and Interleukin-6 (IL-6) Signaling Pathways
Nguyen, V.-A. T., & Gao, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35492 · Cited by 28
Cited by
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Thymoquinone: Potential cure for inflammatory disorders and cancer
Woo, C. C., Kumar, A. P., Sethi, G., & Tan, K. H. B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.09.029 · Cited by 541
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients
Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., Blosser, R. L., Tam, A. J., Bruno, T., Zhang, H., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60083 · Cited by 507
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Metadata
- Authors
- Johnston, P. A., & Grandis, J. R.
- Venue
- Molecular Interventions
- Publisher
- CLOCKSS Archive
- Published
- 2011-02-01
- Volume
- 11
- Issue
- 1
- Pages
- 18-26
- ISSN
- 1534-0384 (ISSN-L)
- OpenAlex
- W1991013609
- Cited by
- 406
- References
- 38
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.